ADJUVANT PUBLICATIONS & ABSTRACTS

Adjuvant data


Evidence / Adjuvant

Prediction of Chemotherapy Benefit by MammaPrint in HR+HER2- Early Stage Breast Cancer Revealed by the FLEX Registry of Real World Data

Title: Prediction of Chemotherapy Benefit by MammaPrint® in HR+HER2- Early Stage Breast Cancer Revealed by the FLEX Registry of Real World Data  Authors: Adam Brufsky*, Kent Hoskins, Henry Conter, Pond Kelemen, Mehran Habibi, Laila Samian, Robert Maganini, Rakshanda Rahman, Laura Lee, Eduardo Dias, Regina Hampton, Beth Seiling, Cynthia Osborne, Read More

Association of MammaPrint With Gene Expression Pathways Predictive of Resistance to Cyclin-Dependent Kinase Inhibition

Title: Association of MammaPrint® With Gene Expression Pathways Predictive of Resistance to Cyclin-Dependent Kinase Inhibition Background: Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) have become a first-line targeted treatment in combination with endocrine therapy for patients with recurring HR+HER2- breast cancer (BC) and have recently been added to the Read More

70‑Gene signature‑guided adjuvant systemic treatment adjustments in early‑stage ER+ breast cancer patients: 7‑year follow‑up study

Title: 70‑Gene signature‑guided adjuvant systemic treatment adjustments in early‑stage ER+ breast cancer patients: 7‑year follow‑up of a prospective multicenter cohort study Publication: Breast Cancer Research and Treatment 2024 Authors: Eline E. F. Verreck, Anne Kuijer, Julia E. C. van Steenhoven, José H. Volders, Annette W. G. van der Velden, Read More